Innovent Biologics Raises $25M

Innovent Biologics Inc., which is manufacturing “monoclonal antibodies,” has raised $25 million in Series B financing. The money comes from Lilly Asia Ventures and from Fidelity Biosciences and Fidelity Growth Partners Asia. Innovent’s antibodies are to be marketing in China and elsewhere around the globe.

North AmericaUSBriefs